Otonomy (Otonomy) Growth Rank : 0 (As of May. 12, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Otonomy Growth Rank?

Otonomy has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Otonomy Growth Rank Related Terms

Thank you for viewing the detailed overview of Otonomy's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Otonomy (Otonomy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4796 Executive Drive, San Diego, CA, USA, 92121

Website

https://www.otonomy.com

Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.

Executives

Hogan H Michael Iii	director	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster	officer: Chief Scientific Officer	4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii	officer: Chief Technical Officer	1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer	officer: CFO/Ch. Business Offcr & Sec.	C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber	director, officer: President & CEO	C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy	director	C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer	director
Eric J Loumeau	officer: GC & Chief Compliance Officer	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop	officer: Chief Scientific Officer	C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel	officer: Chief Scientific Officer	23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong	director	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022